Wealth Enhancement Trust Services’s Corcept Therapeutics CORT Stock Holding History

Wealth Enhancement Trust Services’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.1K	Buy	+128	New	+$7.73K	﹤0.01%	715

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Wealth Enhancement Trust Services's CORT Position: Q2 2026 in Review

Wealth Enhancement Trust Services opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 128 shares worth $11.1K. The stake represents ﹤0.01% of the portfolio and ranks #715 among its holdings.

321 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Wealth Enhancement Trust Services held 128 shares of Corcept Therapeutics worth $11.1K as of Q2 2026.
Corcept Therapeutics was a new Wealth Enhancement Trust Services position in Q2 2026.
Corcept Therapeutics made up ﹤0.01% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #715 holding.
321 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.